These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 38696027)

  • 21. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
    Yosipovitch G; Gooderham MJ; Ständer S; Fonacier L; Szepietowski JC; Deleuran M; Girolomoni G; Su JC; Bushmakin AG; Cappelleri JC; Feeney C; Chan G; Thorpe AJ; Valdez H; Biswas P; Rojo R; DiBonaventura M; Myers DE
    Am J Clin Dermatol; 2024 Jan; 25(1):127-138. PubMed ID: 37624488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis.
    Yosipovitch G; de Bruin-Weller M; Armstrong A; Wu JJ; Herranz P; Thaçi D; Delevry D; Bagousse GB; Zhang R; Shumel B; Rossi AB; Chao J
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):2147-2157. PubMed ID: 34714527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.
    Simpson EL; Blauvelt A; Silverberg JI; Cork MJ; Katoh N; Mark T; Schneider SKR; Wollenberg A
    Am J Clin Dermatol; 2024 Jan; 25(1):139-148. PubMed ID: 37804473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis.
    Thyssen JP; Bewley A; Ständer S; Castro C; Misery L; Kim BS; Biswas P; Chan G; Myers DE; Watkins M; Alderfer J; Güler E; Silverberg JI
    Dermatology; 2024; 240(2):243-253. PubMed ID: 38081155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.
    Chiricozzi A; Ortoncelli M; Schena D; Gori N; Ferrucci SM; Babino G; Napolitano M; Fargnoli MC; Stingeni L; Rossi M; Romanelli M; Balestri R; Pellegrino M; Parodi A; Bertoldi AM; Palazzo G; Antonelli F; Pitino A; Tripepi G; Fabbrocini G; Balato A; Marzano AV; Girolomoni G; Ribero S; Peris K
    Am J Clin Dermatol; 2023 Nov; 24(6):953-961. PubMed ID: 37322324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS).
    Silverberg JI; Simpson EL; Calimlim BM; Litcher-Kelly L; Li X; Sun X; Leshem YA
    Dermatol Ther (Heidelb); 2022 Dec; 12(12):2817-2827. PubMed ID: 36333616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS).
    Silverberg JI; Leshem YA; Calimlim BM; McDonald J; Litcher-Kelly L
    Curr Med Res Opin; 2023 Oct; 39(10):1289-1296. PubMed ID: 37691437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.
    Silverberg JI; DeLozier A; Sun L; Thyssen JP; Kim B; Yosipovitch G; Nunes FP; Gugiu PC; Doll HA; Eichenfield LF
    Health Qual Life Outcomes; 2021 Oct; 19(1):247. PubMed ID: 34688290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
    Silverberg JI; Thyssen JP; Simpson EL; Yosipovitch G; Ständer S; Valdez H; Rojo R; Biswas P; Myers DE; Feeney C; DiBonaventura M
    Am J Clin Dermatol; 2021 Jul; 22(4):541-554. PubMed ID: 33954933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study.
    Katoh N; Ohya Y; Murota H; Ikeda M; Hu X; Ikeda K; Liu J; Sasaki T; Raymundo EM; Teixeira HD; Saeki H
    Dermatol Ther (Heidelb); 2023 Jan; 13(1):221-234. PubMed ID: 36401761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.
    Silverberg JI; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Costanzo A; Rosmarin D; Lynde C; Liu J; Gamelli A; Zeng J; Ladizinski B; Chu AD; Reich K
    J Allergy Clin Immunol; 2022 Mar; 149(3):977-987.e14. PubMed ID: 34403658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
    Paller AS; Flohr C; Eichenfield LF; Irvine AD; Weisman J; Soung J; Pinto Correia A; Natalie CR; Rodriguez Capriles C; Pierce E; Reifeis S; Gontijo Lima R; Armengol Tubau C; Laquer V; Weidinger S
    Dermatol Ther (Heidelb); 2023 Jul; 13(7):1517-1534. PubMed ID: 37318750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.
    Alexis A; de Bruin-Weller M; Weidinger S; Soong W; Barbarot S; Ionita I; Zhang F; Valdez H; Clibborn C; Yin N
    Dermatol Ther (Heidelb); 2022 Mar; 12(3):771-785. PubMed ID: 35297025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study.
    Katoh N; Ikeda M; Ohya Y; Murota H; Hu X; Liu J; Niiyama H; Sasaki T; Raymundo EM; Saeki H
    Dermatol Ther (Heidelb); 2024 Jan; 14(1):213-232. PubMed ID: 38127188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of five patient-reported outcomes for atopic dermatitis severity in adults.
    Silverberg JI; Margolis DJ; Boguniewicz M; Fonacier L; Grayson MH; Ong PY; Fuxench ZC; Simpson EL
    Br J Dermatol; 2020 Jan; 182(1):104-111. PubMed ID: 30972740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with Moderate-to-Severe Atopic Dermatitis.
    Armstrong AW; Hong HC; Calimlim BM; Buessing MG; Crowell MM; Silverberg JI
    Dermatol Ther (Heidelb); 2024 Sep; 14(9):2457-2465. PubMed ID: 39078584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: Results from two randomized phase 3 trials.
    Simpson EL; Rahawi K; Hu X; Chu AD; Nduaka C; Jazayeri S; Lio P; Lynde C; Schuttelaar MLA
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1863-1870. PubMed ID: 37184290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
    Paller AS; Pinter A; Wine Lee L; Aschoff R; Zdybski J; Schnopp C; Praestgaard A; Bansal A; Shumel B; Prescilla R; Bastian M
    Adv Ther; 2024 Mar; 41(3):1046-1061. PubMed ID: 38194047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study.
    Merola JF; Chiou AS; During E; Costanzo A; Foley P; Alfalasi A; Gogate S; Pinter A; Dodiuk-Gad R; Simon D; Tauber M; Weller R; Pereyra-Rodriguez JJ; Ardeleanu M; Wu J; Ozturk ZE
    Br J Dermatol; 2023 Nov; 189(6):685-694. PubMed ID: 37562034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).
    Simpson EL; Gadkari A; Worm M; Soong W; Blauvelt A; Eckert L; Wu R; Ardeleanu M; Graham NMH; Pirozzi G; Sutherland ER; Mastey V
    J Am Acad Dermatol; 2016 Sep; 75(3):506-515. PubMed ID: 27268421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.